US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.57 against a street estimate of 1.48 — a beat of 6.1%.
Analysts rate Collegium Pharmaceutical Inc a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $48.86.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.77% |
| HHG PLC | 5.61% |
| Principal Financial Group Inc | 5.01% |
| Amvescap Plc. | 4.89% |
| Fuller & Thaler Asset Management Inc | 4.61% |
| Renaissance Technologies Corp | 4.51% |
| State Street Corp | 4.38% |
| Massachusetts Financial Services Company | 4.20% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 COLLEGIUM PHARMACEUTICAL, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company announced execution of accelerated share repurchase (ASR) agreement on | 2026-08-13 |
| Quarterly report · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Product revenues (6 months ended June 30, 2026): $393,398 thousand, up from $365 | 2026-08-06 |
| Results announced · Q3 2026 COLLEGIUM PHARMACEUTICAL Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 Total Product Revenues: $199.9 million, up 6% year-over-yea | 2026-08-06 |
| Shareholder vote results · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 14, 2026 • 32,406,969 total shares entitled to vote as | 2026-05-15 |
| Acquisition completed · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed acquisition of AZSTARYS® on May 12, 2026 for approximately $6 | 2026-05-12 |
| Quarterly report · Q1 2026 COLLEGIUM PHARMACEUTICAL, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Product revenues Q1 2026: $193.5 million (up from $177.8 million in Q1 2025 | 2026-05-07 |
| Proxy statement · Q2 2026 COLLEGIUM PHARMACEUTICAL PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect eight director nominees to one-year terms until the 2027 | 2026-04-07 |
| Annual report FY2025 COLLEGIUM PHARMACEUTICAL, INC. – FORM 10-K SUMMARY (YEAR ENDED DECEMBER 31, 2025) HEADLINE NUMBERS • Company is a biopharmaceutical firm commerciali | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Collegium Pharmaceutical Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.